Financial Engines Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Financial Engines Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$313K	Buy	631 +10	+2%	+$4.43K	﹤0.01%	489
2026 Q1	$277K	Sell	621 -32	-5%	-$14.9K	﹤0.01%	479
2025 Q4	$296K	Buy	653 +25	+4%	+$10.8K	﹤0.01%	470
2025 Q3	$246K	Buy	628 +3	+0.5%	+$1.25K	﹤0.01%	500
2025 Q2	$278K	Buy	+625	New	+$288K	﹤0.01%	460
2020 Q3	–	Sell	-827	Closed	-$240K	–	257
2020 Q2	$240K	Buy	+827	New	+$224K	﹤0.01%	177
2018 Q1	–	Sell	-12	Closed	-$2K	–	233
2017 Q4	$2K	Buy	+12	New	+$1.78K	﹤0.01%	159

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Financial Engines Advisors's VRTX Position: Q2 2026 in Review

Financial Engines Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.6% in Q2 2026, buying an estimated $4.43K and bringing the position to 631 shares worth $313K. The position accounts for ﹤0.01% of the portfolio, ranked #489.

Financial Engines Advisors first reported a position in VRTX in Q4 2017 and has held it in 7 quarters since. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Financial Engines Advisors held 631 shares of Vertex Pharmaceuticals worth $313K as of Q2 2026.
Financial Engines Advisors bought 10 Vertex Pharmaceuticals shares in Q2 2026, an estimated $4.43K.
Vertex Pharmaceuticals made up ﹤0.01% of Financial Engines Advisors's portfolio in Q2 2026, its #489 holding.
Financial Engines Advisors first reported a position in Vertex Pharmaceuticals in Q4 2017 and has held it in 7 quarters since.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Financial Engines Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.